-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NI-004 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NI-004 in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NI-004 in Alzheimer's Disease Drug Details: NI-004 is under development for...
-
Product Insights
Serbia Gov – Nis Tech Park Expansion – Central Serbia
The Serbia Gov – Nis Tech Park Expansion – Central Serbia involves the expansion of a state-owned tech park in the southern city of Nis, Serbia. Equip yourself with the essential tools needed to make informed and profitable decisions with our Serbia Gov – Nis Tech Park Expansion – Central Serbia report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Solid Tumor Drug Details: Voyager-V1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus To...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NILK-2301 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NILK-2301 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NILK-2301 in Solid Tumor Drug Details: NI-2301 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NILK-2301 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NILK-2301 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NILK-2301 in Metastatic Colorectal Cancer Drug Details: NI-2301 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IKS-03 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IKS-03 in Mantle Cell Lymphoma Drug Details: IKS-03 (LCB-73, NI-2201)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IKS-03 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IKS-03 in Follicular Lymphoma Drug Details: IKS-03 (LCB-73, NI-2201) is under...